Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
M Tsuboi, RS Herbst, T John, T Kato… - … England Journal of …, 2023 - Mass Medical Soc
Background Among patients with resected, epidermal growth factor receptor (EGFR)–
mutated, stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy …
mutated, stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy …
[HTML][HTML] Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer …
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer …
[HTML][HTML] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
SS Ramalingam, J Vansteenkiste… - … England Journal of …, 2020 - Mass Medical Soc
Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
[HTML][HTML] Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
D Planchard, PA Jänne, Y Cheng… - … England Journal of …, 2023 - Mass Medical Soc
Background Osimertinib is a third-generation epidermal growth factor receptor–tyrosine
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
Osimertinib is the only Food and Drug Administration‐approved third‐generation epidermal
growth factor receptor (EGFR) tyrosine‐kinase inhibitor (TKI). A meta‐analysis was …
growth factor receptor (EGFR) tyrosine‐kinase inhibitor (TKI). A meta‐analysis was …
[HTML][HTML] Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
JC Soria, Y Ohe, J Vansteenkiste… - New England journal …, 2018 - Mass Medical Soc
Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer: updated results from the phase III randomized ADAURA trial
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
[HTML][HTML] ADAURA: phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical …
Introduction Currently, the role of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors as adjuvant therapy for early-stage non–small-cell lung cancer after complete …
inhibitors as adjuvant therapy for early-stage non–small-cell lung cancer after complete …
Postprogression outcomes for osimertinib versus standard-of-care egfr-tki in patients with previously untreated egfr-mutated advanced non–small cell lung cancer
D Planchard, MJ Boyer, JS Lee, A Dechaphunkul… - Clinical Cancer …, 2019 - AACR
Purpose: In the phase III FLAURA study, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free …
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free …
Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study
Y Cheng, Y He, W Li, H Zhang, Q Zhou, B Wang… - Targeted Oncology, 2021 - Springer
Background In the global FLAURA study, first-line osimertinib, a third-generation irreversible
tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly …
tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly …